646-P: Efficacy and Safety of Evogliptin plus Metformin Added to Insulin Therapy in Elderly Indian Patients with Type 2 Diabetes

Abstract

Objective: The combination of evogliptin plus metformin and insulin has known to be effective for the treatment of type 2 diabetes (T2D). However, longitudinal efficacy and safety for elderly patients have not been established. Here, we evaluated whether Evogliptin plus metformin added to insulin therapy safely improved glycemic control for T2D patients older than 65 years of age. Method: Thirty two T2D patients (male/female 20/12; age 76.2± 6.3 years, HbA1c 8.4±0.8%, DOD 6.9±2.1 years) who were administrated insulin were recruited and Evogliptin (5 mg) plus Metformin (500 mg) was added to their treatment regimen. Before and 6 months after adding Lira, we assessed metabolic parameters and the data from CGM. Result: Six months after adding evogliptin plus metformin, HbA1c ( from 8.4±0.8% to 7.2±1.2%; P=0.003) and body weight ( from 62.8±8.3 kg to 61.2±4.6 kg, P=0.006) were significantly improved despite the daily dose ( from 58.5±11.2 IU/day to 45.63±14.4 IU/day, P=0.005) and number of insulin injections per day being reduced. CGM analysis revealed that SD and ≥180 mg/dL AUC were significantly decreased and hypoglycemic events were not increased. Furthermore, 22% of patients with suboptimal glycemic control (A1C>7%) achieved a composite outcome consisting of improvement in A1C, weight loss and insulin dose reduction. Conclusion: These results suggest that the administration of evogliptin plus metformin could safely improve glycemic control and reduce body weight in elderly patients with T2DM undergoing insulin therapy. The reduction of glucose fluctuation and number of insulin injections may improve the quality of life of elderly T2D patients, especially those who require social support. Disclosure S. Guha: None. R. Ranjan: None. A. Gaurav: None. P. Ranjan: None.